• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Apixaban is superior to rivaroxaban in patients with atrial fibrillation and valvular heart disease

byGrace YinandKiera Liblik
October 31, 2022
in Cardiology, Chronic Disease, Hematology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In comparison to rivaroxaban, apixaban was associated with a lower rate of bleeding events and embolic events amongst adults with both atrial fibrillation (AF) and valvular heart disease (VHD).

2. There were no significant differences in all-cause mortality between apixaban and rivaroxaban observed amongst adults with both AF and VHD.

Evidence Rating Level: 2 (Good)

Study Rundown: AF and VHD are cardiac conditions associated with an increased risk of stroke and death. Treatment for AF and VHD often includes anticoagulation agents, which decrease the risk of stroke but can increase the risk of bleeding. Apixaban and rivaroxaban are two forms of direct oral anticoagulants frequently prescribed to manage AF and VHD. This study was a retrospective cohort study comparing the efficacy and safety profile of apixaban against rivaroxaban amongst adults with both AF and VHD who have already been enrolled in continuous treatment with medications. It was predominantly interested in understanding whether the rates of bleeding events or embolic events were different between apixaban and rivaroxaban in adults with both AF and VHD. Secondarily, it aimed to understand whether there was a significant difference in death from any cause between the two. Results found that apixaban was associated with a lower risk of bleeding events and embolic events than rivaroxaban and that there were no significant differences in the rate of death from any cause. Although this study demonstrated that apixaban may be associated with greater safety and efficacy than rivaroxaban, it is significantly limited by the effects of confounding through exposure misclassification and residual confounding. Further, its short follow-up time limits long-term inferences. As such, further studies with longer-term follow-up and greater reduction of bias through the form of randomized controlled trials are necessary to more precisely understand the efficacy and safety profile of apixaban and rivaroxaban in AF and VHD.

Click to read the study in AIM

In-Depth [retrospective cohort]: This study was a retrospective active comparator cohort-study design comparing the effectiveness and safety profile of apixaban against rivaroxaban amongst adults (>18 years old) with both AF and VHD on pharmacology treatment for at least 12 months continuously. In total, 33,907 patients were included, of which 23,712 received apixaban and 10,195 received rivaroxaban. The primary outcome of interest was efficacy in terms of rates of ischemic stroke or systemic embolism per 1,000 person-years of follow-up. Results of the primary analysis found that apixaban was associated with lower rates of ischemic strokes or systemic embolism when compared with rivaroxaban (Hazard Ratio [HR], 0.57; 95% confidence interval [CI], 0.40-0.80). Further, apixaban was associated with a lower risk of bleeding events in comparison to rivaroxaban (HR, 0.51; 95% CI, 0.41-0.62). Results of secondary analysis found no differences in all-cause mortality (HR, 1.10; 95% CI, 0.97-1.24). As some outcomes of interest (such as bleeding events) were measured through hospital records, mild to moderate events not severe enough to warrant hospitalization were not able to be captured. Further, a lack of validated definition of VHD may have led to unidentified cardiac conditions which increase the risk for embolus. Overall, this study demonstrates that apixaban may be associated with a better safety and efficacy profile than rivaroxaban. Further trials investigating whether a causative relationship exists are required before consensus treatment selection recommendations can be consolidated.

Image: PD

RELATED REPORTS

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis

#VisualAbstract: Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: apixabanatrial fibrillationcardiologychronic diseasehematologyrivaroxabanvalvular heart disease
Previous Post

Patients with HER2-positive advanced breast cancer and pathological complete response to neoadjuvant systemic therapy may not require surgical intervention

Next Post

Sequencing of androgen-deprivation therapy with radiotherapy for non-metastatic prostate cancer

RelatedReports

Intravenous contrast may not increase risk of acute kidney injury
Chronic Disease

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

February 3, 2023
Physical therapy reduces pain in adults with knee osteoarthritis
Chronic Disease

High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis

February 3, 2023
#VisualAbstract: Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
StudyGraphics

#VisualAbstract: Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

February 3, 2023
Nonleg venous thromboses associated with PE, longer ICU stay
Chronic Disease

Efanesoctocog alfa is efficacious in treating severe hemophilia A

February 2, 2023
Next Post
Patient Basics: Enlarged Prostate (Benign Prostatic Hyperplasia)

Sequencing of androgen-deprivation therapy with radiotherapy for non-metastatic prostate cancer

Large proportion of late preterm infants and older admitted to the NICU

Neonatal docosahexaenoic acid supplementation is associated with higher IQ scores at five years of age

Neurocognitive deficits in congenital heart disease may not worsen with age

Vitamin D3 supplementation not effective in preventing ventricular hypertrophy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options